Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of PF-00299804 vs erlotinib in advanced non-small cell lung cancer after prior chemotherapy failure
2008-005235-14Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dacomitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: progression-free survival. Started Nov 2008; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-005235-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005235-14.